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Let me warn you at the beginning: this is going to be one long
rant. I am tired of people using “impact factors.” Originally,
Thomson Reuters developed the journal impact factor so librarians
could prioritize journal subscriptions, but the measurement has
been abused. Now, far too often, this measure is used as a quick
and blind assessment of the quality of scientiﬁc research. In the
last few years I visited two European biological institutes whose
directors described the importance of the work done by their
scientists not by telling me what discoveries they made, but by
telling me the impact factors of the journals in which their
scientists had published. And I am seeing a disturbing trend in
the CVs of job applicants and junior faculty members where lists of
publications are supplemented with how many citations the
publications have received and which papers have had “News
and Views” type articles written about them. Even in my depart-
ment, consideration for tenure always seems to start with
a question about whether the candidate has published in Cell,
Nature, or Science (the CNS journals). I also suspect that some grant
reviewers look for these journals as a quick means of judging
scientiﬁc quality.
So where have highly inﬂuential works in biology been
published, at least the seminal papers for which Nobel Prizes in
Medicine or Physiology or in Chemistry (when biological) have
been given? Looking through the information on the nobleprize.
org web site, I found 73 articles for the prizes given in the 25 years
between 1988 and 2012. Only half were published in the CNS
journals. My favorites among the papers in non-CNS journals
(for personal reasons) are the publication of the discovery of GFP
by Osamu Shimomura in the Journal of Cellular and Comparative
Physiology, Roger Tsien's ﬁrst paper on modifying GFP in the
Proceeding of the National Academy of Sciences, the beginning of
C. elegans genetics by Sydney Brenner in Genetics, and the post-
embryonic cell lineage of C. elegans by John Sulston and Bob
Horvitz in Developmental Biology. Clearly, the journal does not
make an article important.
The real problem is that all too often administrators, search
committees, review panels, and (to be honest) we ourselves seek an
easy way to assess the importance of research done by others. Such
short cuts are attractive because evaluating other people's science
requires hard work and a willingness to devote time to the evaluation,
especially when the research is not directly in our ﬁeld. Moreover,
different people have different views of what actually constitutes
importance. A particularly disturbing trend in biology, both in the
United States and abroad, is that the more translational the work is,
the more signiﬁcant it is deemed. Our work should be evaluated based
on its novelty and how much it advances our knowledge, not on
where it is published or whether or not it relates to human health.
In this context, I would like to consider the paper that was
published by Shimomura et al. in J. Cell. Comp. Physiol. (59: 223–
239) in 1962. This paper describes the discovery of the biolumi-
nescent protein aequorin and, in probably the only footnote that
led to a Nobel Prize, the ﬂuorescent protein we now call GFP. The
work was not designed to address a translational question; it was
designed to address a biological question: how does the jellyﬁsh
generate light, compared, for example, to other cases of biolumi-
nescence. The surprising answer was that aequorin generated light
in the presence of calcium, a previously unknown way to regulate
bioluminescence. The discovery of GFP was accidental; Shimo-
mura noticed that aequorin produced blue light instead of the
green light observed in the jellyﬁsh and searched for a protein that
could convert the blue light to green. Both discoveries are inter-
esting and groundbreaking science. I would say that the paper was
exceptionally important (especially for me), but did it have an
impact? Certainly not immediately (nor did Watson and Crick's,
1953 Nature paper), although later aequorin became the ﬁrst
cellular calcium indicator and GFP became a valuable marker of
living cells and tissues. Is the work more or less important because
of these applications? I donot think so.
So many people are upset about journal impact factors that a
revolt has begun. Recently an effort spearheaded by the American
Society for Cell Biology issued a Declaration of Research Assessment
(DORA), which argued against the use of the journal impact factor
and set reasonable guidelines for assessing scientiﬁc research for
research institutions, funding agencies, researchers, and publishers.
The declaration can be read at http://am.ascb.org/dora/, where you
can also add your name to those that support it. I have done so, and
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/developmentalbiology
Developmental Biology
http://dx.doi.org/10.1016/j.ydbio.2014.02.005
0012-1606
Developmental Biology 388 (2014) 145–146
so has the Society for Developmental Biology (SDB). I encourage you
to add your name as well.
Last month Randy Schekman wrote about the “tyranny” of
the CNS journals and declared that he was ceasing to publish in
them (http://www.theguardian.com/commentisfree/2013/dec/09/
how-journals-nature-science-cell-damage-science). The cynical
might say that this was easy for him to say, since he is the
editor-in-chief of eLife and had just won a Nobel Prize. I think,
however, that he is expressing a frustration with scientiﬁc publish-
ing that is felt throughout our community. I am not sure if the
cold-turkey approach he advocates is correct. The usual argument
that I have heard against this approach is that it penalizes our
students and postdocs, who need to make a name for themselves
(frankly, though, I feel that many of the senior people that say this
are actually thinking about themselves). Nonetheless, we do have
a problem with serial submission of papers (if Nature doesnot like
the paper, let us send it to Science).
One suggestion missing from the Schekman letter was where
people should send their papers. I would like to make a strong plea
that people should send their papers to journals that are the
ofﬁcial publications of professional scientiﬁc societies, such as
SDB's journal Developmental Biology. (Some journals from profes-
sional societies are published by the societies, some are not.
Developmental Biology, which was original published by Academic
Press, is now published by Elsevier.) These journals have editors
and reviewers who are leaders in their ﬁelds and who care deeply
about the quality of the work, not whether the work is trendy. In
addition, support of these journals has itself an impact: the
support of the professional societies. A considerable proportion
of the money that funds our annual meeting, the regional meet-
ings, and all the other efforts that SDB undertakes, including our
educational initiatives, comes from royalties from subscriptions to
Developmental Biology.
A few years ago I asked Eve Marder, Head of the Division of
Science at Brandeis and past president of the Society for Neu-
roscience, how she coped with students and postdocs who wanted
to send their work to CNS journals. She replied that she would let
them submit their papers anywhere they wanted, but if the paper
was rejected, it had to be submitted next to a professional society
journal or a similar journal. For those of you who feel that you
want to change the tyranny of the CNS journals, but are not ready
to join a publishing 12-step program, the Marder method may be
the way to start. This is what I have decided to do in my lab.
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